Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTIVE: Tranexamic Acid or Terlipressin for Initial Emergency Treatment of Mild to Severe Hemoptysis
NCT04961528Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Mar 2022
- Primary completion
- Dec 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hemoptysis comparing Terlipressin, Tranexamic Acid and Placebo (3 arms). Primary endpoint: Number of patients with complete or partial resolution of hemoptysis without the use of any interventional procedure at 3 days. Started Mar 2022; status: completed.
02
Drugs
tranexamic acidterlipressin
03
Conditions
hemoptysis
Beyond the preview
Go deeper on NCT04961528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04961528.